Dongkook Pharmaceutical is expected to accelerate its shift toward a third-generation management structure under the company’s founding family.
The company said on the 20th that it carried out executive appointments for eight people, including promoting Kwon Byung-hoon, head of a unit and the eldest son of Chairman Kwon Ki-beom, to director (treatment) effective April 1.
Born in 1995, Kwon double-majored in policy analysis & management and economics at Cornell University in the United States.
He previously worked at Boston Consulting Group, Mirae Asset Venture Investment and Magna Investment, and joined Dongkook Pharmaceutical’s financial planning office in April 2024.
Dongkook Pharmaceutical posted record consolidated revenue of 926.9 billion won last year. Operating profit rose 20.1% to 96.6 billion won over the same period, and the market views the company as likely to reach 1 trillion won in annual sales this year.
The following is the list of executive promotions.
◇ Executive promotions (effective April 1)
△ Yeom Seon-ho, vice president, Health Functional Foods Business Division △ Lee Jae-wook, vice president, Production Headquarters △ Heo Jeong-moo, vice president, Communications Headquarters △ Kang Seong-oh, executive director, ETC Business Headquarters △ Kwon Byung-hoon, director (treatment), Financial Planning Office △ Myeong Chang-hoon, director (treatment), ETC Business Headquarters △ Yoo Ho-myeong, director (treatment), Production Headquarters △ Choi Moon-seok, director (treatment), Sales Management Department
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.